MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
P/E ratio for MDxHealth SA (MDXH)
P/E ratio as of 2023: -2.37
According to MDxHealth SA's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.37. At the end of 2022 the company had a P/E ratio of -2.09.
P/E ratio history for MDxHealth SA from 2004 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -2.37 |
| 2022 | -2.09 |
| 2021 | -3.76 |
| 2020 | -3.33 |
| 2019 | -1.74 |
| 2018 | -2.13 |
| 2017 | -4.87 |
| 2016 | -4.20 |
| 2015 | -3.42 |
| 2014 | -2.73 |
| 2013 | -2.23 |
| 2012 | -2.23 |
| 2011 | -2.29 |
| 2010 | -1.44 |
| 2009 | -0.77 |
| 2008 | -1.00 |
| 2007 | -0.89 |
| 2006 | -1.06 |
| 2005 | -1.08 |
| 2004 | -0.64 |